Evidence map›Paper›PMID 40117502›Full record

ReviewTrends in psychiatry and psychotherapy2025

Perspectives on the ketogenic diet as a non-pharmacological intervention for major depressive disorder.

Jade Shelp, Cristiano Chaves, Alexander Terpstra, Elena Koning, Fabiano A Gomes, Jennifer Fabe, Vitor Breda, Nicole Laurent, Christopher Palmer, Elisa Brietzke

Abstract readReview
In one paragraph

Review in Trends in psychiatry and psychotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jade ShelpDepartment of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada. Centre for Neuroscience Studies (CNS), Queen's University, Kingston, ON, Canada.
Cristiano ChavesDepartment of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada. Centre for Neuroscience Studies (CNS), Queen's University, Kingston, ON, Canada.
Alexander TerpstraSt. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Elena KoningDepartment of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada. Centre for Neuroscience Studies (CNS), Queen's University, Kingston, ON, Canada.
Fabiano A GomesDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
Jennifer FabeMcMaster Children's Hospital, Hamilton, ON, Canada.
Vitor BredaDepartment of Psychiatry, London Health Sciences Centre, Western University, London, ON, Canada.
Nicole LaurentFamily Renewal, Inc DBA Mental Health Keto, Vancouver, WA, United States.
Christopher PalmerMcLean Hospital, Belmont, MA, USA.schoolHarvard Medical School, Boston, MA, USA.
Elisa BrietzkeDepartment of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada. Centre for Neuroscience Studies (CNS), Queen's University, Kingston, ON, Canada.

Funding

PSI Foundation 22-07Queen's University
6 · The paper itself

Abstract

objectiveMajor depressive disorder (MDD) is a prevalent mood disorder characterized by persistent low mood and anhedonia, significantly impacting cognitive function and daily living. Despite available pharmacological treatments, nearly one-third of individuals with MDD do not achieve adequate symptom relief with conventional treatments. The ketogenic diet (KD), a high-fat, low-carbohydrate diet that induces ketosis, has emerged as a potential non-pharmacological intervention for MDD. The objective of this study was to provide a comprehensive perspective on the current knowledge and gaps regarding the potential antidepressant effect of the KD, emphasizing its safety, efficacy, and mechanistic pathways.

methodsThis narrative review synthesizes data from preclinical and clinical studies on the effects of KD on mood, cognitive function, and its potential as an antidepressant. Mechanistic insights from animal and human studies are explored to elucidate possible pathways through which KD may exert its effects on MDD.

resultsEvidence from animal models suggests that KD may reduce depressive-like behaviors and improve cognitive function. Preliminary human studies, including case reports and observational studies, indicate potential benefits such as mood stabilization, increased energy, and reduced depression severity. Proposed mechanisms include immune-inflammatory regulation, correction of mitochondrial dysfunction, and neurotransmitter modulation. However, key gaps remain, particularly regarding the therapeutic window, long-term efficacy, and specific mechanisms of action in MDD.

conclusionsKD represents a promising avenue for further investigation as a non-pharmacological treatment of MDD. Further research is needed to establish its clinical utility, identify predictors of response, and assess its feasibility as a treatment option for MDD.

Indexed as

Diet, KetogenicMajor Depressive DisorderAnimalsHumansketogenic dietketosisMajor depressive disordermetabolismnutrition

Identifiers

PMID40117502
PMCPMC12978508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.